Yahoo
NSE - Delayed Quote INR

Laurus Labs Limited (LAURUSLABS.NS)

2,342.40 +98.40 (+4.39%)
As of 10:00:31 AM GMT+5:30. Market Open.
LAURUSLABS.NS Q2 2027 earnings call
Replay the call for the latest insights.
Chart Range Bar
Loading chart for LAURUSLABS.NS
  • Previous Close 2,244.00
  • Open 2,246.60
  • Bid 2,335.10 x --
  • Ask 2,342.10 x --
  • Day's Range 2,206.10 - 2,342.40
  • 52 Week Range 917.95 - 2,342.40
  • Volume 2,622,891
  • Avg. Volume 2,289,163
  • Market Cap (intraday) 1.266T
  • Beta (5Y Monthly) 0.34
  • PE Ratio (TTM) 112.56
  • EPS (TTM) 20.81
  • Earnings Date Oct 29, 2026
  • Forward Dividend & Yield 2.40 (0.11%)
  • Ex-Dividend Date May 8, 2026
  • 1y Target Est 1,712.36

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug product development, and biologics development. In addition, the company offers non-human ingredients; rare disease therapeutics; and finished dosages. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

www.lauruslabs.com

7,059

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

LAURUSLABS.NS
111.62%
S&P BSE SENSEX (^BSESN)
12.82%

1-Year Return

LAURUSLABS.NS
141.84%
S&P BSE SENSEX (^BSESN)
11.98%

3-Year Return

LAURUSLABS.NS
552.17%
S&P BSE SENSEX (^BSESN)
15.88%

5-Year Return

LAURUSLABS.NS
361.07%
S&P BSE SENSEX (^BSESN)
25.27%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY26
Revenue 18.12B
Earnings 2.79B
Profit Margin 15.41%

Q1

FY26

Q2

FY26

Q3

FY26

Q4

FY26

0
5B
10B
15B
11.0%
12.0%
13.0%
14.0%
15.0%

Analyst Insights

View More

Analyst Price Targets

900.00 Low
1,712.36 Average
2,342.40 Current
2,520.00

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
As of 10/28/2026
  • Market Cap

    1.18T

  • Enterprise Value

    1.21T

  • Trailing P/E

    107.85

  • Forward P/E

    --

  • PEG Ratio (current)

    157.18

  • Price/Sales (ttm)

    16.23

  • Price/Book (mrq)

    22.33

  • Enterprise Value/Revenue

    16.59

  • Enterprise Value/EBITDA

    57.77

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    15.04%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    72.7B

  • Net Income Avi to Common (ttm)

    10.93B

  • Diluted EPS (ttm)

    20.81

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.14B

  • Total Debt/Equity (mrq)

    46.37%

  • Levered Free Cash Flow (ttm)

    --

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: